Origin and prognostic value of circulating KRAS mutations in lung cancer patients

O. Gautschi, B. Huegli, A. Ziegler, M. Gugger, J. Heighway, D. Ratschiller, P. C. Mack, P. H. Gumerlock, H. J. Kung, R. A. Stahel, D. R. Gandara, D. C. Betticher

Research output: Contribution to journalArticlepeer-review

81 Citations (Scopus)


Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalCancer Letters
Issue number2
Publication statusPublished - Sept 8 2007
Externally publishedYes


  • Circulating DNA
  • KRAS
  • Lung cancer
  • Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Origin and prognostic value of circulating KRAS mutations in lung cancer patients'. Together they form a unique fingerprint.

Cite this